Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A preliminary cross-sectional study found that different sleep complaints had different associations. It did not establish benzodiazepines as a nightmare-prevention treatment.
A secondary analysis linked the pandemic period with higher benzodiazepine use among people who inject drugs with an HCV history. It was an exploratory period comparison.
A rat experiment found improved skin perfusion after adding vatinoxan to medetomidine–midazolam sedation. It did not isolate a midazolam effect.
A small randomized study found favorable satisfaction and fewer observed apnea events with virtual-reality distraction. Both groups had spinal anesthesia, so VR did not replace surgical analgesia.
A retrospective inpatient study counted lorazepam among commonly administered medicines. Incomplete standardized response documentation limited comparative efficacy and safety conclusions.
An observational study reported shorter delirium duration in one medication category than another. Treatment selection and measurement limitations prevent interpreting the difference as a randomized treatment effect.
A small cancer-surgery study linked receptor-agonist use with delirium and described a multidisciplinary intervention. Its observational findings did not isolate a single drug effect.
A receptor-pharmacology review discussed alpha-5-selective ligands in airway experiments. Relaxation of preconstricted tissue was not evidence of a proven human asthma treatment.
A systematic-review protocol set out ventilation, withdrawal, delirium, and safety outcomes. The supplied protocol did not report that clonidine reduced benzodiazepine requirements or improved survival.
A ten-year outpatient emergency study found benzodiazepines commonly involved in adolescent recreational poisoning. It counted presentations and could not identify repeated visits by the same patient.
A case report titled as a fatal overdose actually describes discharge after recovery. Its clonazepam and cardiovascular-drug exposure cannot be summarized faithfully from the title alone.
A case report describes persistent fever and altered consciousness after correction of severe hyponatremia. Catatonic signs and subsequent lorazepam response informed the authors’ diagnosis.
A factorial trial protocol planned to compare remimazolam and other sedatives with three analgesic adjuncts. It supplied a study design, not evidence of which combination reduced fatigue.
A commentary argued for education, policy, and AI-assisted prescribing review. It did not report a trial showing that an algorithm reduced benzodiazepine harm.
A systematic review of five trials suggested more durable sleep benefits from CBT-I. Its short-term medication comparison rested on very low-grade evidence.
A case report attributed an unexplained coma to benzodiazepine exposure using several clinical observations. Its urine result and unusual MRI appearance did not identify a specific ingested product or dose.
A review of trials published during 2010–2018 described different treatment time courses. Earlier symptom change with clonazepam in a cited comparison did not establish superior outcomes at every later assessment.
A cross-sectional Australian study found lower EQ-5D-5L scores among residents prescribed benzodiazepines. The association did not establish that the medication caused the difference.
A Dravet-syndrome mouse model showed changes in social and memory-related tasks after clonazepam. The result did not establish treatment efficacy for autism in humans.
A cost-utility model estimated higher costs and fewer quality-adjusted life years from long-term benzodiazepine prescribing. Its outputs were model projections, not measured losses for an individual patient.
A nerve-agent model found dose-dependent seizures and neuropathology despite delayed treatment. The work chiefly characterizes an animal model, rather than comparing human treatment regimens.
A case report described recovery of function after a combined treatment change. It could not isolate clonazepam’s independent contribution to movement control.
A research-network paper identified evidence gaps after initial seizure treatment fails. Its historical review and network plans should not be mistaken for completed comparative results.
A laboratory study found mineralization-related changes after exposing a porcine pulp-derived cell line to midazolam. It did not demonstrate tooth repair from clinical sedation.
A retrospective outpatient study linked Passiflora extract and cognitive behavioral therapy with greater dose reduction. Treatment selection and a coarse therapy measure limit causal interpretation.
A twenty-patient ICU series reported lower medication requirements and autonomic signs after an adjunct was started. Its before-and-after design did not establish prevention of intubation or seizures.
A small comparative trial reported similar withdrawal-score improvement among completers. Its handling of complicated withdrawal limits claims of equivalent protection against severe outcomes.
A small crossover trial favored midazolam over melatonin on sedation and satisfaction. Both were premedications before intravenous sedation, so the study did not compare either oral agent as the entire procedure regimen.
A ten-week active-comparator trial found large anxiety-score reductions in both groups. It tested a particular standardized extract, not all products containing the same plant.
A retrospective pediatric study associated infusion within fifteen minutes with shorter seizure-control time. Its small cohort did not establish a sharp biological cutoff or prevention of epilepsy.